The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow.

Pfizer has reached agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, regarding lawsuits filed in the U.S. District Court for the District of Delaware. Vyndamax remains the market leader ...

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

By Michael Erman NEW YORK, June 6 (Reuters) - Pfizer presented data on Saturday that showed a monthly dose of an experimental ...

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...

The natural GLP-1 hormone survives in the body for only a few minutes before it is broken down. Drug developers overcome this ...